Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,005.56 -10.19 (-1.00%)
Streaming Delayed Price Updated: 3:51 PM EDT, May 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? ↗
Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market. 
Via The Motley Fool
News headline image
Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook ↗
Amphastar Pharmaceuticals (NASDAQ:AMPH) executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to... 
Via MarketBeat
News headline image
This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst ↗
William Blair gives Kailera Therapeutics ($KLRA) an Outperform rating. Learn why analysts see a competitive edge in their GLP-1 assets. 
Via Benzinga
News headline image
Is Novo Nordisk's Rebound for Real--or Just a Head Fake? ↗
The worst might be in the rearview mirror. 
Via The Motley Fool
Eli Lilly & Co. (NYSE:LLY) Passes the "Little Book That Makes You Rich" Growth Screen ↗
Via Chartmill
News headline image
Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss ↗
Eli Lilly data shows patients maintain weight loss with Foundayo or lower-dose Zepbound after switching from injectable therapies. 
Via Benzinga
News headline image
1 of Wall Street’s Favorite Stock to Target This Week and 2 We Avoid
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
Topics Retirement
News headline image
Q1 Earnings Roundup: Amphastar Pharmaceuticals (NASDAQ:AMPH) And The Rest Of The Pharmaceuticals Segment
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Eli Lilly (LLY) Stock Trades Up, Here Is Why
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.4% in the afternoon session after the stock continued to rally as the co... 
Via StockStory
News headline image
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity ↗
Analysts initiated covered Tuesday of IPO stock, a potential competitor to Lilly and Novo in obesity. 
Via Investor's Business Daily
Topics Initial Public Offering
News headline image
Why Hims & Hers Health Stock Just Crashed ↗
Hims & Hers is unshaken by its earnings miss, with management promising even faster sales growth this year. 
Via The Motley Fool
Topics Earnings Lawsuit
News headline image
The 3 Best S&P 500 Stocks to Buy Now ↗
These growth stocks are benefiting from major tailwinds across cloud computing, digital payments, and healthcare. 
Via The Motley Fool
Topics Artificial Intelligence Credit Cards Economy
News headline image
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:PFE),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Next-generation wellness platforms targeting longevity, metabolism, and performance continue gaining momentum in one of healthcare’s fastest-growing sectors 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Income or Growth: Which Healthcare Stock Fits Your Portfolio Right Now? ↗
It's important to look beyond near-term volatility. 
Via The Motley Fool
Topics Economy Retirement Stocks
BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Next-Generation GLP-1 Candidate as Obesity Drug Market Expands Rapidly
Via Investor Brand Network
The Next Generation of the GLP-1 Revolution Is Already Underway
Via Investor Brand Network
News headline image
The Next Generation of the GLP-1 Revolution Is Already Underway
From BioMedWire
Via GlobeNewswire
News headline image
Is This News From Novo Nordisk a Warning for Eli Lilly Shareholders? ↗
The weight loss drug market is on track to reach almost $100 billion. 
Via The Motley Fool
News headline image
GoodRx (GDRX) Q1 2026 Earnings Call Transcript ↗
GoodRx (GDRX) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Omada Health (OMDA) Q1 2026 Earnings Transcript ↗
Omada Health (OMDA) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There. ↗
The competition is far behind. 
Via The Motley Fool
News headline image
Omada Health Q1 Earnings Call Highlights ↗
Omada Health (NASDAQ:OMDA) reported what executives described as a “milestone quarter” for the first quarter of 2026, highlighting 42% year-over-year revenue growth, expanding margins, and positive... 
Via MarketBeat
Topics Earnings
News headline image
Eli Lilly's Retatrutide Is So Hot, The Unlaunched Weight-Loss Drug Is Already Getting Knocked Off ↗
Eli Lilly's next obesity drug, retatrutide, is so popular it's already getting copied. Can Lilly compete with its own drug? 
Via Investor's Business Daily
News headline image
How This Eli Lilly-Tied IPO Stock Fared In Its First Quarter ↗
IPO stock Omada Health easily beat first-quarter sales expectations Thursday, and announced a deal with drug titan Eli Lilly. 
Via Investor's Business Daily
Topics Initial Public Offering
News headline image
Forget Eli Lilly: These 2 Stocks Have More Upside ↗
Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors. 
Via The Motley Fool
News headline image
Eli Lilly Now Has the World's Best-Selling Drug -- But Does That Make the Stock a No-Brainer Buy? ↗
Mounjaro generated $8.66 billion in sales in the first quarter. 
Via The Motley Fool
News headline image
What the FDA's Latest Proposal Means for Lilly, Novo, and Hims ↗
The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits. 
Via MarketBeat
News headline image
My Top Obesity Stock to Buy and Hold ↗
Most weight-loss stocks are built on future expectations. Eli Lilly is built on current earnings and expanding demand. 
Via The Motley Fool
News headline image
Eli Lilly To Invest $4.5 Billion More In Indiana Manufacturing Sites ↗
Eli Lilly plans to invest $4.5 billion in Indiana, expanding its U.S. manufacturing footprint and supporting new weight-loss treatments. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.